Exploring the reasons behind the high price of crizotinib

Crizotinib (Crizotinib), as a new drug and targeted therapy, is expensive because of multiple factors. The cost of developing new drugs is extremely high. From drug discovery to chemical synthesis to pre-clinical research and clinical trials, each step requires massive financial investment and scientific research support. The stakes involved are extremely high, as most R&D projects can ultimately fail. The successful research and development of crizotinib is undoubtedly the result of countless trials and failures, and the research and development costs behind it are naturally high.

Although crizotinib has significant effects in the treatment of some rare and special diseases, due to its relatively few indications, the market demand is not as huge as that of some common drugs. At the same time, because crizotinib is a new drug, its market competition is relatively small. In this case, pharmaceutical companies often need to set drug prices relatively high in order to recover R&D and production costs and obtain profits.

Crizotinib is mainly suitable for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC), relapsed or refractory systemic anaplastic large cell lymphoma (ALCL), and unresectable, relapsed or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumor (IMT). It works therapeutically by blocking the activity of ALK or ROS1, thereby reducing the growth and spread of cancer cells.

In the domestic market, the price of the original drug of crizotinib is relatively high, and each box of 250mg*60 capsules may cost more than RMB 10,000. Fortunately, this drug has been included in Class B medical insurance, providing certain price concessions for patients who meet the indications. In comparison, some generic drugs on overseas markets are more affordable, but patients still need to be cautious when choosing and ensure the quality and safety of the drugs.